多中心研究揭示哮吼使用皮质类固醇的循证推荐与临床实践之间存在显著差距
该研究回顾性分析2017年意大利两家儿科急诊诊断为哮吼的632例患儿(男性61.1%,平均年龄42.8±55.1个月),描述临床表现、皮质类固醇使用和家庭治疗情况,并比较不同皮质类固醇治疗组的住院时间、住院率和再就诊率。403例(63.8%)在急诊接受了皮质类固醇,其中地塞米松仅1例(0.4%),吸入和口服皮质类固醇分别用于342例(54.1%)和226例(35.8%)。603例(95.4%)被处方家庭治疗,包括吸入(86.2%)和/或口服(43.8%)皮质类固醇,再就诊率为2.8%。实际药品费用估计为遵循推荐时的10倍,作者认为改善对推荐的依从性可带来临床和经济获益。
要点
- 632例哮吼患儿中仅1例(0.4%)在急诊使用地塞米松,403例(63.8%)接受了皮质类固醇但主要为吸入(54.1%)和口服(35.8%)。
- 603例(95.4%)被处方家庭皮质类固醇治疗,其中吸入86.2%、口服43.8%,再就诊率2.8%。
- 实际药品费用估计为遵循推荐时的10倍,提示不遵循推荐带来经济负担。
- 作者认为改善对哮吼治疗推荐的依从性可能带来临床和经济获益。
适用人群与场景
- 2017年在意大利两家儿科急诊诊断为哮吼的儿童,共632例(男性61.1%,平均年龄42.8±55.1个月)。
研究设计与关键结果
- 研究类型为回顾性病历审查,纳入意大利两家儿科急诊2017年诊断为哮吼的632例患儿。
- 急诊皮质类固醇使用:403例(63.8%)接受皮质类固醇,其中地塞米松仅1例(0.4%),吸入皮质类固醇342例(54.1%),口服皮质类固醇226例(35.8%)。
- 家庭治疗:603例(95.4%)被处方家庭治疗,包括吸入皮质类固醇86.2%和/或口服皮质类固醇43.8%。
- 再就诊率为2.8%。
- 实际药品费用估计为遵循推荐时的10倍。
证据类型、等级与局限
- 证据类型:回顾性病历审查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为改善对哮吼治疗推荐的依从性可能带来临床和经济获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Adherence to croup management recommendations has been poorly investigated. This study aimed to describe the treatment patterns in two paediatric emergency departments and analyse the adherence to recommendations.
METHODS: We conducted a retrospective chart review of children diagnosed with croup in two Italian paediatric emergency departments in 2017. Data on clinical presentation, corticosteroid administration and home therapy were collected. Length of stay, hospitalisation and re-access rates were compared among different corticosteroid treatment groups.
RESULTS: We enrolled 632 patients (61.1% males) with a mean age of 42.8 ± 55.1 months. Corticosteroids were administered to 403 (63.8%) children in the emergency departments. Dexamethasone was administered to 1 (0.4%) patient. Inhaled and oral corticosteroids were given to 342 (54.1%) and 226 (35.8%) patients, respectively. Home therapy was prescribed for 603 (95.4%) patients, either with inhaled (86.2%) and/or oral (43.8%) corticosteroids. The re-access rate was 2.8%. The actual pharmaceutical costs were an estimated 10 times higher than they would have been if the recommendations had been followed.
CONCLUSION: A significant gap between the evidence and clinical practice for croup treatment was observed. Improving adherence to the recommendations could lead to clinical and economic benefits.
参考来源
- Pierantoni L, Stera G, Andreozzi L, et al. Multicentre study revealed significant gaps between evidence-based recommendations for using corticosteroids for croup and clinical practice. Acta Paediatr. 2022. PMID: 35751481. doi:10.1111/apa.16468
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。